#Paris #France #Cardiology #Nyra Medical #CARLEN

Nyra Medical Honored with the Jon DeHaan Foundation Award

On June 18, 2026, during the prominent EuroPCR conference in Paris, Nyra Medical was announced as the esteemed recipient of the Jon DeHaan Foundation Award for Cardiovascular Innovation. This recognition is a significant acknowledgment of the company's cutting-edge contributions to the field of structural heart therapies, particularly represented through their novel CARLEN™ System.

The Jon DeHaan Foundation Award is presented to breakthrough innovations in cardiovascular technologies that are expected to improve patient outcomes significantly. When selecting the recipients, various crucial factors come into play, such as clinical needs, unique technological advancements, intellectual property scale, proof of concept, regulatory status, and commercial viability.

Nyra Medical's CARLEN System, designed for transcatheter mitral valve repair, aims to maintain the function of the native valve while expanding treatment alternatives for patients suffering from functional mitral regurgitation (FMR). FMR affects millions globally and often poses significant health risks, yet many patients currently do not have adequate treatment options available to them.

Lori Chmura, the Chief Executive Officer of Nyra Medical, expressed her gratitude following the award announcement: “Receiving this award is an extraordinary honor and provides meaningful validation of our technology and our mission. The CARLEN System was developed to address existing limitations in transcatheter mitral repair methods and to extend treatment options for patients battling functional mitral regurgitation.”

The success of Nyra's CARLEN System follows an encouraging initial human clinical trial, which highlights the promising path for the technology in the healthcare landscape. Dr. Susheel Kodali, a leading expert in structural heart therapies, presented the early clinical results at the EuroPCR event. He remarked on the potential of the CARLEN System to reshape treatment pathways, emphasizing its focus on improving patient care.

The innovative mechanism behind the CARLEN System allows for better leaflet coaptation while preserving natural anatomical structure, ultimately catering to a broader range of functional mitral regurgitation patients, many of whom have historically been underserved. This transformative technology not only provides immediate clinical solutions but also showcases a long-term vision for future therapeutic flexibility.

The Jon DeHaan Foundation has established itself as a preeminent organization championing innovation within cardiovascular medicine. Its commitment to identifying and uplifting technologies that hold the promise of significant patient care improvements is vital in today’s rapidly evolving healthcare environment.

Based on the early promising clinical data presented by Dr. Kodali, the intent to further explore and validate the CARLEN technology underscores a dedication to continuous improvement and adaptation in patient care methodologies. With the EuroPCR accolade, Nyra Medical stands among the vanguard of innovators in the cardiovascular industry.

The award ceremony marked a significant milestone not only for Nyra Medical but also for the broader community dedicated to advancing healthcare outcomes for patients with cardiovascular diseases. As Nyra Medical advances its clinical studies and prepares to share long-term data from their innovative interventions, the anticipation for more favorable outcomes builds within the medical community.

For further details about the award and Nyra Medical's innovations, visit their website at nyramedical.com. Here, users can find insights into upcoming studies and additional information about the CARLEN System’s impact on future cardiovascular treatments.